^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    Biological Dynamics

    i
    Other names: Biological Dynamics
    Related tests:
    Evidence

    News

    28d
    Biological Dynamics and Oregon Health & Science University collaborate on early-stage pancreatic cancer detection study (Biological Dynamics Press Release)
    "Biological Dynamics...announced its collaboration with the Brenden-Colson Center for Pancreatic Care at Oregon Health & Science University (OHSU) to study its ExoVita™ Pancreas assay. The Brenden-Colson Center has a robust, integrated clinical-translational interface to drive innovative patient care and nourish scientific collaborations."
    Licensing / partnership
    |
    ExoVita™ Pancreas
    2ms
    Biological Dynamics launches ExoVita™ Pancreas and enrolls patients in ExoLuminate clinical trial (Biological Dynamics Press Release)
    "Biological Dynamics...announced completion of the analytical and clinical validation of its lab developed test (LDT), ExoVita™ Pancreas in the company’s CLIA certified and CAP accredited laboratory...Using blood-based exosome samples enriched on the proprietary ExoVerita instrument, the ExoVita Pancreas assay measures specific exosomal protein biomarkers and has been demonstrated to detect Stage 1 and Stage 2 pancreatic ductal adenoma carcinoma (PDAC)."
    Launch • Enrollment open
    |
    ExoVita™ Pancreas
    2ms
    Biological Dynamics, Perlmutter Cancer Center at NYU Langone Health collaborate on pancreatic cancer research (Biological Dynamics Press Release)
    "Biological Dynamics...announced a collaboration with the Perlmutter Cancer Center at NYU Langone Health to validate its application for the early detection of pancreatic ductal adenocarcinoma (PDAC)...The collaboration will test retrospective samples from over 200 patients starting this month. The ExoVerita™ platform is being investigated at NYU Langone Health, among other premier institutions, with a goal of advancing treatment options for high-risk PDAC patients."
    Licensing / partnership